c[L-Phe-D-pro-L-Phe-L-trp]

ID: ALA506616

Chembl Id: CHEMBL506616

Cas Number: 210236-47-8

PubChem CID: 44583372

Max Phase: Preclinical

Molecular Formula: C34H35N5O4

Molecular Weight: 577.69

Molecule Type: Protein

Names and Identifiers

Synonyms: CJ-15208 | CJ-15208|c[L-Phe-D-pro-L-Phe-L-trp]|CHEMBL506616|210236-47-8|SCHEMBL12368055|BDBM50268462|AKOS040748141|(3S,6S,9S,12R)-3,9-dibenzyl-6-(1H-indol-3-ylmethyl)-1,4,7,10-tetrazabicyclo[10.3.0]pentadecane-2,5,8,11-tetrone|(3S,6S,9S,14aR)-6-((1H-indol-3-yl)methyl)-3,9-dibenzyldecahydropyrrolo[1,2-a][1,4,7,10]tetraazacyclododecine-1,4,7,10-tetraone

Canonical SMILES:  O=C1N[C@@H](Cc2ccccc2)C(=O)N2CCC[C@@H]2C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@H]1Cc1c[nH]c2ccccc12

Standard InChI:  InChI=1S/C34H35N5O4/c40-31-27(18-22-10-3-1-4-11-22)37-33(42)30-16-9-17-39(30)34(43)29(19-23-12-5-2-6-13-23)38-32(41)28(36-31)20-24-21-35-26-15-8-7-14-25(24)26/h1-8,10-15,21,27-30,35H,9,16-20H2,(H,36,40)(H,37,42)(H,38,41)/t27-,28-,29-,30+/m0/s1

Standard InChI Key:  GIZJWWQFOGQPRY-GCXHJFECSA-N

Alternative Forms

1. Parent:

   

   ALA506616

   c[L-Phe-D-pro-L-Phe-L-trp]

Molecule Features

Natural Product: Yes

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Protein

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 577.69

Molecular Weight (Monoisotopic): 577.2689

AlogP: 2.65

#Rotatable Bonds: 6

Polar Surface Area: 123.40

Molecular Species: NEUTRAL

HBA: 4

HBD: 4

#RO5 Violations: 1

HBA (Lipinski): 9

HBD (Lipinski): 4

#RO5 Violations (Lipinski): 1

CX Acidic pKa: 10.83

CX Basic pKa: ┄

CX LogP: 3.19

CX LogD: 3.19

Aromatic Rings: 4

Heavy Atoms: 43

QED Weighted: 0.28

Np Likeness Score: 0.46

References

1. Dolle RE, Michaut M, Martinez-Teipel B, Seida PR, Ajello CW, Muller AL, DeHaven RN, Carroll PJ..  (2009)  Nascent structure-activity relationship study of a diastereomeric series of kappa opioid receptor antagonists derived from CJ-15,208.,  19  (13): [PMID:19464172] [10.1016/j.bmcl.2009.04.105]

2. Carroll FI, Carlezon WA..  (2013)  Development of κ opioid receptor antagonists.,  56  (6): [PMID:23360448] [10.1021/jm301783x]

3. Aldrich JV, Senadheera SN, Ross NC, Ganno ML, Eans SO, McLaughlin JP..  (2013)  The macrocyclic peptide natural product CJ-15,208 is orally active and prevents reinstatement of extinguished cocaine-seeking behavior.,  76  (3): [PMID:23327691] [10.1021/np300697k]

4. Helal MA, Habib ES, Chittiboyina AG..  (2017)  Selective kappa opioid antagonists for treatment of addiction, are we there yet?,  141  [PMID:29107424] [10.1016/j.ejmech.2017.10.012]

5. De Marco R, Bedini A, Spampinato S, Cavina L, Pirazzoli E, Gentilucci L..  (2016)  Versatile Picklocks To Access All Opioid Receptors: Tuning the Selectivity and Functional Profile of the Cyclotetrapeptide c[Phe-d-Pro-Phe-Trp] (CJ-15,208).,  59  (19): [PMID:27607020] [10.1021/acs.jmedchem.6b00420]

6. Smith MT, Kong D, Kuo A, Imam MZ, Williams CM..  (2022)  Analgesic Opioid Ligand Discovery Based on Nonmorphinan Scaffolds Derived from Natural Sources.,  65  (3.0): [PMID:34995453] [10.1021/acs.jmedchem.0c01915]

Source

Source(1):

• Scientific Literature